Zymergen Revenue and Competitors



Total Funding



Estimated Revenue & Valuation

  • Zymergen's estimated annual revenue is currently $19.6M per year.(i)
  • Zymergen received $400.0M in venture funding in December 2018.
  • Zymergen's estimated revenue per employee is $150,846
  • Zymergen's total funding is $974.1M.
  • Zymergen's current valuation is $562.2M. (January 2022)

Employee Data

  • Zymergen has 130 Employees.(i)
  • Zymergen grew their employee count by -56% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

Founded in 2013 and based in the San Francisco Bay Area, Zymergen integrates automation, machine learning, and genomics to rapidly accelerate the pace of scientific advancement. We treat the genome as a search space, leveraging machine learning to make discoveries far beyond the bounds of human intuition. In doing so, we deliver economic value, material diversity and performance capabilities not previously possible. Want to join the team Apply at zymergen.com/careers

keywords:saas, Biotechnology,Cleantech,Hardware,Hardware Peripherals,Healthcare,Pharmaceuticals,Robotics,Solar Power,Wind Power


Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Zymergen News

2022-04-17 - Should You Accumulate Zymergen Inc (ZY) in Chemicals Industry?

Zymergen Inc's score of 41 means it scores higher than 41% of stocks in the industry. Zymergen Inc also received an overall rating of 37,...

2022-04-13 - Why Shares of Zymergen Are Plunging Today

After zooming higher yesterday, shares of synthetic-biology specialist Zymergen (ZY 8.70%) are moving swiftly in the other direction today.

2022-04-13 - Why Shares of Zymergen Are Plunging Today

After shares of Zymergen soared 23% yesterday, investors seem content to collect profits and run during today's trading session.

2021-05-04 - Zymergen Hires Former Apple Executive and Ford Motor Leader as Chief Manufacturing Officer

EMERYVILLE, Calif., May 4, 2021 /PRNewswire/ -- Biofacturing leader Zymergen today announced Aindrea Campbell is joining the company as Chief Manufacturing Officer, developing and leading Zymergen's global manufacturing and supply chain activities. "Aindrea has a proven track record of runnin ...

2021-04-23 - Zymergen's stock jumps after $500M IPO

Shares of Zymergen rose more than 21% in the company's first day of trading on the Nasdaq, closing at $37.65 apiece. At that price, the synthetic biology company was worth nearly $3.6 billion based on the number of shares outstanding, compared with the $2 billion valuation it received from priva ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

Zymergen Funding

DateAmountRoundLead InvestorsReference
2015-06-17$44.0MAData CollectiveArticle
2016-10-12$130.0MBSoftBank GroupArticle
2018-12-14$400.0MCSoftBank Vision FundArticle

Zymergen Executives

Jay FlatleyChairman and Acting CEO
Zach SerberChief Science Officer & Co-Founder
Enakshi SinghCFO
Subodh DeshmukhChief Development Officer
Lincoln GermainChief Commercial Officer
Georgia BrownExecutive Assistant to Chief People Office & Chief Financial Officer
Mina KimChief Legal Officer
Prasad GanesanChief Of Staff
Jack GoldChief Marketing Officer
Judy GilbertChief People Officer
Subodh DeshmukhChief Development Officer
Aaron KimballCTO
Aindrea CampbellChief Manufacturing Officer
Amanda TreleavenChief Compliance Officer
Jackie P.Executive Assistant to Chief Legal Officer
Dmitriy RyaboyChief Technology Officer
Phil RomansVice President, Product Portfolio Management
John WarnerSenior Vice President, Chemistry and Distinguished Research Fellow
Rizvan KhawarVP, Deputy General Counsel
Devin ScannellSVP, Drug Discovery and Executive Team Member
Stephen VanVP, Business Development
Erica CarlisleVP Development, Development & Operations
Aimee DavidExecutive Assistant to Founder & VP of Operations
Niels Lynge AgerbækVice President
Peter SommerVice President, Test Development & Enzymology
Jesse AhrendtVice President, Quality
Gaby OlazabalVP - Head of Transformation Office
John SchiffhauerVice President Intellectual Property
Colin SouthVice President Strategy
Steve CollettiSenior Vice President
Robert FlemingVice President Research and Technology